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‘remission’ states may discontinue treatment. The relative risk of discontinuation
on venlafaxine (2.37 at Week 6) compared with agomelatine is applied to the dis-
continuation rate of venlafaxine in the Australian population. When a patient is off
treatment, they have a reduced likelihood of moving to the ‘remission’ and ‘well’
states compared with patients remaining on treatment. Costs are in 2010 dollars
and costs and outcomes discounted at 5%. RESULTS: Compared with venlafaxine,
treatment with agomelatine yields 0.011 additional quality-adjusted life-years
(QALY) at an incremental cost of AU$196 giving an incremental cost-effectiveness
ratio (ICER) of AU$18,098/QALY. The presentation will discuss the issues raised by
the PBAC and how these were addressed. CONCLUSIONS: When the impact of a
lower discontinuation rate is modelled, agomelatine is a cost-effective treatment
for MDD versus venlafaxine.
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OBJECTIVES: Schizophrenia patients who suffer from frequent relapses have their
cognition damaged and need heavy medical resource utilization such as long-term
hospitalization. Schizophrenia incurs a burden not only to patients and caregivers,
but also to society. This study aims to carry out cost-utility analysis of ‘paliperidone
palmitate long acting injection (PLAI)’ that improves drug adherent compared with
atypical oral antipsychotics (risperidone, olanzapine, aripiprazole and paliperi-
done) from a payer’s perspective. METHODS: The study subjects are non-adherent
schizophrenia patients with exacerbation of symptoms. A decision-tree model was
constructed to compare the clinical and economic outcomes of PLAI and oral com-
parator over 1 year. Clinical data such as relapse rate, EPS rate, suicide rate and
non-adherent rate as well as utility weight were obtained from published litera-
ture. Direct medical cost data were also obtained from a domestic literature. Sen-
sitivity analyses were performed on PLAI drug cost and major variables. RESULTS:
: Based on model estimates, PLAI showed some advantages of reducing hospital-
ization and increasing utility over its comparators. Total direct medical costs were
KRW 5.62million for PLAI, and KRW 4.71million for comparators. Incremental cost-
effectiveness ratio of PLAI versus oral atypical antipsychotics was KRW 2.22million
per quality-adjusted life year (QALY). Sensitivity analyses showed that hospitaliza-
tion cost per day and frequency of hospitalization per year had greatest influence
on the result. CONCLUSIONS: The use of PLAI may result in improved health effect
and QALY compared with atypical antipsychotics. Despite its higher cost, PLAI can
be considered as one of the options for non-adherent patients in schizophrenia, as
it reduces hospitalization and increases quality of life.
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OBJECTIVES: To better understand antidepressant-related weight gain and its as-
sociation with medication adherence in employees experiencing depression.
METHODS: Employed individuals (18 years of age) with diagnosed depression
(excluding bipolar disorder) completed a web-based computer-generated 25-min-
ute survey (population identified by Harris InteractiveTM). Antidepressant adher-
ence was quantified via 8-item Morisky Medication Adherence Scale (MMAS-8)
where scores of 0, 1-2, and 3-8 were categorized as high, medium, and low adher-
ence, respectively. Weight gain was measured using the Toronto Side Effects Scale
which measures medication-related side effects in the 2-weeks preceding the sur-
vey, and analyzed as a 4-level ordinal variable (none,2lbs,4lbs, and7lbs),
where “none” was the referent category. Gender stratified cumulative logit models
were used to estimate effect of weight gain on medication adherence. Binary logit
models were used to estimate effect of weight gain on each of the 8 MMAS-8
questions. RESULTS: Of 1521 survey respondents, 872 (57%) reported current anti-
depressant use (60.6% female, mean age 49.9  13.5 years). A higher proportion of
female patients (39%) belonged to the “low adherence” category compared to male
patients (31%) (p0.02). Compared to males with no weight gain, odds of being in a
poorer overall adherence category were greater in the7lbs weight gain category
(odds ratio [OR]2.33; p 0.09 ); likewise, odds of reporting not taking medication
for “reasons other than forgetting” were greater for 4lbs (OR2.35; p0.05) and
7lbs (OR2.92; p0.04 ). Among female patients, odds of reporting “reductions
or stoppage of medication use” increased with increasing weight gain of 2lbs
(OR1.72; p0.05), 4lbs (OR2.00; p0.06), and 7lbs (OR2.50; p.07).
CONCLUSIONS: These data suggest that antidepressant-related weight gain may
result in diminished adherence to prescribed medication. Additional research
should focus on further quantification of this association as medication non-ad-
herence may be closely associated with depressive relapse.
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OBJECTIVES: Existing evidence-based treatments for the anxiety condition Post-
Traumatic Stress Disorder (PTSD) have an overall success rate of only 20% to 30%
with pharmacologic therapies. Thus, an urgent need exists for alternative PTSD
treatment options. This investigation examined the impact of local anesthetics
delivered via stellate ganglion block (SGB) injection on mitigating PTSD severity,
thereby improving health-related quality of life (HRQoL). METHODS: A retrospec-
tive case series (n8) who received one (n6) or more (n2) SGB treatments con-
sisting of 0.5% bupivacaine was identified at one private practice setting. A wide
range of demographic and clinical data was extracted from medical records. PTSD
severity and dimensions of HRQoL were examined using standardized valid instru-
ments. T-tests were used to compare mean changes in PTSD severity scores, with
p0.05 denoting significance. RESULTS: The majority of cases were male (88%) and
veterans (63%). The average age was 43.4 years (range, 29 to 66 years). Mean fol-
low-up time after SGB treatment was 17.5 days (range, 1 to 59 days). Among cases
who received one SGB injection, significant improvements in overall PTSD severity
were observed (p0.02) including symptoms related to the psychological dimen-
sions of avoidance (p0.03), and hyperarousal (p0.01). On average, these patients
experienced a 41% decrease in PTSD severity (range, 6% to 70%). Relative to cases
who received one SGB injection, the two cases with multiple SGB injections re-
ported greater levels of PTSD symptom relief (58.6% and 73.4%), with substantial
improvements in all three PTSD-related psychological clusters, namely re-experi-
encing, avoidance, and hyperarousal symptoms. All patients reported substantial
improvements in HRQoL and none experienced adverse events. CONCLUSIONS:
Local anesthetics delivered via SGB show promise as an alternative treatment for
refractory PTSD. Double-blind randomized placebo-controlled trials are needed to
generate further confirmatory evidence for sound clinical decision-making and
health advocacy to expand SGB’s indication for PTSD.
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OBJECTIVES: The SF-6D and the EQ-5D are two ways to generate utility values.
Many studies compared these methods, but there is limited information in schizo-
phrenia. The objective of this study is to compare the SF-36 and EQ-5D utility values
and to compare their evolution over time in European schizophrenic patients.
METHODS: We used data from EuroSC, a multicenter 2-year cohort study con-
ducted in France, England and Germany. In several subpopulations, we used
paired-samples t-test to identify significant differences at baseline, and calculated
the Pearson correlation. Changes from baseline were also calculated at 6 and 24
months. RESULTS:The overall sample was composed of 1088 patients. Mean utility
scores were significantly different at baseline (EQ-5D: 0.73 (0.28); SF-6D: 0.65 (0.09);
p0.0001), and values modestly correlated (r  0.314, p0.001). The SF-6D scores
distribution was found to be normal, contrary to EQ-5D, highly negatively skewed.
Range of values was much larger for EQ-5D (EQ-5D: [-0.35; 1.00]; SF-6D: [0.32; 0.87]).
The difference was also significant at baseline when considering subpopulations,
with higher values for EQ-5D. When considering patients whose illness was stable
or had improved at 6 months, change from baseline was significantly different
from 0 for EQ-5D (mean 0.067 (0.29) p0.0001), but not for SF-6D (0.007 (0.11)
p0.28). The result was not significant for patients whose illness worsened (EQ-5D:
-0.040 (0.29) p0.19; SF-6D: -0.007 (0.12) p0.56). The same trends were observed
after 24 months, using depression scores to evaluate improvement or worsening,
and when adjusted on the baseline value. CONCLUSIONS: In our study, EQ-5D
tends to generate wider and higher scores in schizophrenic patients. EQ-5D seems
to be more sensitive to change than SF-6D. The method by which QALYs have been
computed is of importance in an economic evaluation.
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OBJECTIVES:The aim of this study is to describe the Quality of Life (QoL) of children
with Attention Deficit Hyperactivity Disorder (ADHD) and their parents. The objec-
tive was to compare QoL in different states of compliance to medication (methyl-
phenidate and atomoxetine), in remission status after medication use or being
naïve to medication using EQ-5D (proxy version for the children) and KID-
SCREEN-10 (KS) questionnaires. METHODS: A cross-sectional, retrospective, sur-
vey was performed using online questionnaires (September 1, 2010 to October 3,
2010) that was completed by the parent/caregiver. Inclusion criterion was being a
parent/caregiver of a child (age 6-18 years) diagnosed with ADHD. Parents/caregiv-
ers were contacted via the Dutch patient organization. Subgroups of medication
use were defined by parents as ‘optimal’, ‘suboptimal’, ‘remission’ and ‘medication
use stopped’ according to current medication intake. The fifth group were children
who never used ADHD-medication. Qol data of the child and the parent were
compared in these different groups of medication intake, using Students’ t-tests for
continuous variables and Kruskal-Wallis tests for categorical data. RESULTS:Anal-
yses were performed on 873 returned questionnaires. The QoL in the classified
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groups are described here for children (proxy EQ-5D and KS) and parents (EQ-5D).
Optimal compliance: proxy EQ-5D 0.8257, KS 47.5152, EQ-5D 0.8331. Suboptimal
compliance: proxy EQ-5D 0.7321, KS 42.7671, EQ-5D 0.8050. Medication use stopped:
proxy EQ-5D 0.7635, KS 42.5969, EQ-5D 0.8169. Remission after medication use:
proxy EQ-5D 0.8518, KS 45.8929, EQ-5D 0.8220. Naïve to medication: proxy EQ-5D
0.7719, KS 43.3744, EQ-5D 0.7899. CONCLUSIONS: Children with a good compliance
to medication and naïve children have a better QoL compared to non-compliant
children and children who stopped treatment (non-remission). The QoL of children
in remission is better than the QoL of children using medication. QoL of parents
follows a similar pattern.
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OBJECTIVES: To test the characteristics of a QUICK Questionnaire-Short version
(Q10) as diagnostic instrument for wearing-off phenomenon (WO) in Parkinson’s
disease (PD) patients. METHODS: Observational, cross-sectional, multicenter, and
national study developed in clinical practice. The study was developed in two
consecutive phases: I, to determine the sensitivity and specificity of Q10; and II: to
assess the usefulness (investigators) and the ability and ease of use (patients) of
Q10 questionnaire. Furthermore, the prevalence of WO among PD patients consec-
utively attending the specialist was also assessed (phase II). Patients 30 years old
at the onset of the disease with5 years from diagnosis and under treatment were
selected.RESULTS: In phase I, 162 patients were included, 67.49.7 years old, 53.8%
males, and 3.11.4 years from diagnosis. Most of them (85%) were in Hoehn-Yahr
stage 2-3. WO was presented in 64.8% (33.3% mild; 31.5% moderate/severe). Q10
was completed in 6.64.9 minutes. With two positive responses the Q10 showed
good sensitivity (90%) and moderate specificity (70%) and with 3 positive responses
both values reached an arbitrarily hypothesized 75% threshold (sensitivity: 81%;
specificity: 75%). The mean usefulness Q10 score was good [7.3 (1.6), scale 1-10]. In
phase II, most patients considered Q10: easy to understand (80.6%), reflect their
present situations (78.8%), and useful to communicate discomfort to the doctor
(80.6%). The prevalence of WO among the total PD patients attending to the neu-
rologist was of 59.0%, higher in males (64.9%), Hoehn-Yahr staging (80%, 3-4 stage)
and in patients with more time of PD evolution (71.9%). CONCLUSIONS: The Q10 is
a useful instrument for screening and diagnosis of WO, showing good sensitivity
and specificity, as well as, good usefulness, ability and ease to use. Almost two out
of three PD patients attending to the neurologist presented WO.
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OBJECTIVES: Develop a cross-cultural adaptation, English to Spanish, of the Clin-
ically Useful Depression Outcome Scale (CUDOS): a validated instrument to assess
depressive symptoms in patients with major depressive disorder (MDD).
METHODS: CUDOS is a brief self-administered scale with 18 items assessing all of
the DSM-IV inclusion criteria for MDD, psychosocial impairment and patients’
quality of life. Three independent translators (2 Spanish and 1 English) performed
forward-backward translations of the original scale. Draft version was reviewed by
an expert panel (4 general practitioners, 1 psychiatrist, and 2 psychologists) and
tested in 19 adult patients with MDD. Regarding experts’ and patients’ responses,
comprehension and importance (C/I) of each item were evaluated using a Likert
scale ranging from 0 (lowest level of C/I) to 4 (highest level of C/I). Furthermore,
feasibility, ceiling and floor effects and reliability were preliminary analyzed.
RESULTS: According to experts’ criteria, mean C/I values of items were over 2
points (comprehension mean range: 3.25-4 & importance mean range: 2.5-4). Re-
garding patients’ responses, acceptable mean values in comprehension (range:
2.26-3.37) were obtained. However, 4 items were modified to improve comprehen-
sion: loss of interest in usual activities, psychomotor retardation, indecisiveness
and hopelessness Patients reported low importance scores in items related to
thoughts of death (mean 1.42), suicidal ideation (mean 1.26), guilt (mean 1.79),
hypersomnia (mean 1.37) and insomnia (mean 1.78). Missing data was only
found in 2 patients. Internal consistency was high (Cronbach  .886), Neither item
ceiling nor floor effects were observed and patients perceiving a moderate to severe
psychosocial impairment obtained higher CUDOS scores –indicating a higher im-
pact- than those with mild or null impairment (Mann-Whitney U9.500; p.019).
Finally, the Spanish version of the CUDOS was reached by consensus.
CONCLUSIONS: The original CUDOS instrument was culturally adapted into Span-
ish. Psychometric analyses are needed to validate this measure in Spain.
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OBJECTIVES: FDA guidance on the use of Patient Reported Outcomes (PRO) for
product labeling claims emphasizes the importance of documented evidence of
patient input in PRO instrument development. A review of existing PROs used in
Major Depressive Disorder (MDD) suggested the need to conduct qualitative re-
search with patients with MDD to better understand their experience of MDD and
develop an evaluative instrument with content validity. The aim of this study was
to develop such a measure. METHODS: Ten MDD severity-specific focus groups
(n3-4 patients per group; total n38) with adult patients between the ages of 18
and 65 having a clinician-confirmed diagnosis of MDD and varying in severity
levels as defined by the DSM-IV TR criteria were conducted in January 2009.
Grounded theory data collection and analysis methods were used including an
open-ended discussion guide, an iteratively developed coding scheme, and the
comparison of coded segments of patients’ quotes to identify the patient experi-
enced signs and symptoms of MDD. Saturation of concepts, where no new relevant
information emerges in later interviews, was assessed. A new PRO instrument for
MDD was developed; cognitive interviews (n20) were conducted to test its content
validity in terms of item relevance and comprehension, comprehensiveness, in-
structions, recall period and response categories.RESULTS:Thirty-five unique con-
cepts falling into the following 6 domains: emotional symptoms; ideation symp-
toms; neuro-vegetative or somatic symptoms; physical impact; social impact; and
cognitive impact were elicited. Concept saturation was achieved for each of the
symptom concepts across severity levels. The MDD PRO instrument includes 15
daily and 21 weekly items. Cognitive interviews supported its content validity.
Items were revised, deleted, or moved from daily to weekly assessment based on
cognitive interview results CONCLUSIONS: Rigorous qualitative research resulted
in the development of a PRO measure for MDD with supported content validity; its
psychometric properties and responsiveness requires assessment.
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OBJECTIVES: Substitution therapy is commonly used across the world for the treat-
ment of opioid dependence (OD), yet little evidence exists examining country-
specific differences between acceptance and effectiveness of this treatment. The
purpose of this study was to examine differences between patient demographics,
treatment accessibility, and attitudes toward substitution therapy among OD pa-
tients in Germany and Italy.METHODS:A telephonic survey, initiated by the Italian
Federation of Operators of Dependences Departments and Services, examining
substitution therapy was administered to OD patients across two countries: Ger-
many (n200) and Italy (n378). The survey assessed experiences prior to and
during substitution therapy. RESULTS: Italian patients reported being in better
physical and mental health than German patients (p’s 0.001); were more likely to
get information about substitution therapy from family members than German
patients (8.9% vs. 3.2%, 2  5.22; p  0.05); and were more likely to report that it
was either very easy or fairly easy to find a doctor from whom they could receive
substitution treatment than German patients (89.9% vs. 68.7%, 2  40.35; p 
0.001). In contrast, German patients were more likely to get information from other
drug users (63.9% vs. 47.7%, 2 10.72; p 0.01) or their family physicians (14.6% vs.
4.3%, 2  14.59; p  0.0001), and were also more likely than Italian patients to
misuse their substitution drug by either snorting (11.5% vs. 3.2%, 2  15.94; p 
0.0001) or injecting it (18.5% vs. 11.1%, 2  6.05; p  0.05). CONCLUSIONS: The
present results highlight key differences in patient attitudes and experiences re-
garding substitution therapy. Differences in social and institutional attitudes, in
addition to cultural norms and health care policies, may explain the present find-
ings, which demonstrate the complexity of the OD population.
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OBJECTIVES: This research uses Cox regression to analyze relapse patterns of
adults treated for substance use disorder (SUD). The objective is to evaluate the role
psychosocial, treatment and environmental characteristics play in the relapse pro-
cess. While relapse is a much-studied phenomenon, there is no research describing
in detail how the risk of relapse changes over time (especially in the months im-
mediately following primary treatment) given known protective factors. Since SUD
is a chronic relapsing disorder, it is important to understand ways treatment gains
can be maintained. METHODS: Subjects are 408 adults discharged between 2000-
2009 from an ASAM-defined Level 1.A primary inpatient treatment program. Data
were collected via a 215-item questionnaire as part of the treatment program’s
annual outcomes evaluation. The sampling frame was people who successfully
completed treatment and who gave consent. The response rate was 56 percent. The
researchers obtained the treatment records of each person completing the ques-
tionnaire and matched the treatment outcomes from the questionnaire to treat-
ment and sociodemographic variables present in the treatment records. A compre-
hensive data set was created from these two sources. Data were analyzed using
Cox proportional hazard regression. RESULTS: Statistically significant covariates
include: home environment variables (those with supportive people at home are
3.17 times less likely to relapse; those with supportive spouses are 4.91 times less
likely to relapse) and support group variables (those attending self-help meetings
A295V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
